Research programme: vanilloid 1 receptor antagonists - Amorepacific/Schwarz Pharma

Drug Profile

Research programme: vanilloid 1 receptor antagonists - Amorepacific/Schwarz Pharma

Alternative Names: PAC 20030; SPM 95; SPM 955; Vanilloid 1 receptor antagonists - Schwarz/Amorepacific

Latest Information Update: 26 Jun 2012

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Amorepacific
  • Developer UCB
  • Class Analgesics
  • Mechanism of Action TRPV cation channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 26 Jun 2012 Discontinued - Preclinical for Pain in Germany (unspecified route) before 2012
  • 17 Jul 2007 Preclinical development is ongoing
  • 04 Jan 2007 Schwarz Pharma has been acquired by UCB
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top